Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decreases blood fibrinolytic activity in the rat.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Thrombosis research. Supplement

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0049-3848(88)80013-6PMID 3144762
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasminogen activator inhibitor induced by lipopolysaccharide injection in the rat Zymographic analysis

  1987cited by this paper
• Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers.

  1986cited by this paper
• Modulation of endothelial cell hemostatic properties by tumor necrosis factor

  1986cited by this paper
• Effects of interferon-gamma and tumor necrosis factor-alpha on the expression of an Ia antigen on a murine macrophage cell line.

  1986cited by this paper
• Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture

  1986cited by this paper
• Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells.

  1986cited by this paper
• Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells

  1986cited by this paper
• Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor.

  1986cited by this paper
• Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.

  1986cited by this paper
• Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro.

  1986cited by this paper
• Identity of tumour necrosis factor and the macrophage-secreted factor cachectin

  1985cited by this paper
• Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor.

  1985cited by this paper
• Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors.

  1985cited by this paper
• Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.

  1985cited by this paper
• Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.

  1984cited by this paper
• Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex.

  1984cited by this paper
• Characterization of a plasminogen activator secreted by cultured bovine aortic endothelial cells.

  1982cited by this paper
• Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro.

  1981cited by this paper
• Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates.

  1979cited by this paper
• Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein.

  1978cited by this paper
• Synthesis of a fibrinolytic activator and inhibitor by endothelial cells.

  1977cited by this paper
• An endotoxin-induced serum factor that causes necrosis of tumors.

  1975cited by this paper

• Similar Pathophysiological Mechanisms Between Osteoarthritis and Vascular Disease.

  2024influential citation
• Solving the New Puzzle(s) 2014-2022: Flammer Syndrome Probably Represents a Mild Endophenotype of Raynaud’s Phenomenon Mainly Associated with Ocular Disturbances and Also Due to Latent T. gondii Infection

  2023cites this paper
• Proteomic analysis of human articular cartilage unravels the dyscoagulation in osteoarthritis and the potential value of serpinA5 as a biomarker for osteoarthritis

  2021cites this paper
• Metabolic Syndrome, Obesity, and Osteoarthritis

  2015cites this paper
• Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

  2008cites this paper
• Ceramides in insulin resistance and lipotoxicity.

  2006cites this paper
• Tumor Necrosis Factor Alpha and Gamma Interferon, but Not Hemorrhage or Pathogen Burden, Dictate Levels of Protective Fibrin Deposition during Infection

  2006cites this paper
• TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA)-INDUCED CELL-ADHESION TO HUMAN ENDOTHELIAL-CELLS IS UNDER DOMINANT CONTROL OF ONE TNF RECEPTOR TYPE, (TNF-ALPHA)-INDUCED CELL-ADHESION TO HUMAN ENDOTHELIAL-CELLS CONTROL

  2003cites this paper
• Vascular mechanisms in osteoarthritis.

  2001cites this paper
• Tumor Necrosis Factor-Dependent Adhesions as a Major Protective Mechanism Early in Septic Peritonitis in Mice

  2001cites this paper
• LPS and Cytokine-Activated Endothelium

  2000cites this paper
• Maternal Intrauterine Infection, Cytokines, and Brain Damage in the Preterm Newborn

  1997cites this paper
• Endothelial Function and Malignant Coagulopathy

  1996cites this paper
• Tumor necrosis factor alpha (rhTNF) fails to stimulate angiogenesis in the rabbit cornea

  1996cites this paper
• Increased Expression of Plasminogen Activator Inhibitor-1 in R.rickettssi-infected Endothelial Cells

  1996cites this paper
• Inhibitory effect of the human recombinant tumor necrosis factor on the growth of the Morris hepatoma in rats.

  1995cites this paper
• Inhibiting interleukin-1 and tumor necrosis factor-alpha does not reduce induction of plasminogen activator inhibitor type-1 by endotoxin in rats in vivo.

  1995cites this paper
• Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischemic heart disease. Relevance in superoxide anion generation.

  1994cites this paper
• Changes in Plasma Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Sepsis with Organ Failure

  1994cites this paper
• Increased Secretion of Tumor Necrosis Factor‐α and Interferon‐γ by Mononuclear Leukocytes in Patients With Ischemic Heart Disease Relevance in Superoxide Anion Generation

  1994cites this paper
• Endothelial activation by hydrogen peroxide. Selective increases of intercellular adhesion molecule-1 and major histocompatibility complex class I.

  1993cites this paper
• Hämostasestörungen und Bluttransfusion

  1993cites this paper
• Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55

  1993cites this paper
• On the Fibrinolytic System in Aged Rats, and Its Reactivity to Endotoxin and Cytokines

  1992cites this paper
• Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine.

  1992cites this paper
• Cytokine regulation of hemostatic property and IL-6 production of human endothelial cells

  1992cites this paper
• Use of fibrinogen to enhance the antitumor effect of OK‐432. A new approach to immunotherapy for colorectal carcinoma

  1992cites this paper
• Tumour necrosis factor (TNF) and inflammation

  1992cites this paper
• Time course of IL-6 and TNFα release during endotoxin-induced endotoxin tolerance in rats

  1991cites this paper
• Tumor Necrosis Factor Stimulates Urokinase-Type Plasminogen Activator and Inhibitor Type 1 Production in A549 Lung Carcinoma Cells: Treatment of Monolayer and Tridimensional Cultures

  1991cites this paper
• Time course of IL-6 and TNF alpha release during endotoxin-induced endotoxin tolerance in rats.

  1991cites this paper
• The Changes in Coagulation and Fibrinolysis During Treatment for Cancer

  1991cites this paper
• Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.

  1990cites this paper
• Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit

  1990cites this paper
• Tumour necrosis factor α stimulates the production of pro-urokinase from the A549 lung carcinoma cell line

  1990cites this paper
• Production of plasminogen activator and plasminogen activator inhibitor by bovine lymphatic endothelial cells: modulation by TNF-alpha.

  1990cites this paper
• Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy.

  1990cites this paper
• Effect of Tumor Necrosis Factor on the Human Fibrinolytic System

  1990cites this paper